Talk

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal and Thomas Moreau discuss how bit.bio are working to solve the problem of restricted access to reliable human cells using next-generation precision reprogramming technology.
Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Dr Thomas Moreau

Head of Research

bit.bio

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery
Kam Dhaliwal and Thomas Moreau discuss how bit.bio are working to solve the problem of restricted access to reliable human cells using next-generation precision reprogramming technology.
Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Dr Thomas Moreau

Head of Research

bit.bio

Listen to our talk at ELRIG Drug Discovery Digital to learn how bit.bio’s opti-ox™  technology can generate cells with high consistency and functionality at scale from human iPSCs, including those carrying disease-specific mutations, providing high-quality human models for enhanced research outcomes and drug discovery efficiency.

Dr Thomas Moreau | Head of Research & Kam Dhaliwal | SVP Strategic Alliances

bit.bio

bit.bio talk at ELRIG Drug Discovery Digital

2020

Download resource

Related pages

News Read our latest updates and press coverage
Our platform Discover the cell identity coding platform behind our cells
Join us Explore the latest roles at bit.bio